Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Celcuity Inc.
CELC
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.1B
$106.75
▲ +2.16%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$13.13 - $151.02
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 701.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CELsignia platform using living tumor cells for personalized therapy matching
- Strategic partnership with Pfizer for Gedatolisib development and commercialization rights
- First-mover advantage in functional precision medicine diagnostics for cancer treatment selection
- Multi-indication pipeline potential with platform applicability across cancer types
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Revenue decline expected
Clinical advancement of Gedatolisib toward regulatory approval and commercialization
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-7.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CELC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 14, 2026
Reported EPS of -$0.97 vs -$1.07 consensus (+9.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.3%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$165.00
▲ +54.6% vs $106.75
Latest: Guggenheim · Jun 3, 2026
8 analysts covering